Tonight on CNBC, Jim Cramer interviewed Robert Hugin, COO of Celgene Corporation (NASDAQ:CELG), one name Cramer has been very positive about before. He said many on the Street think Celgene is a one-trick pony with Revlimid, but the best is yet to come. The track record and opportunity is much larger for it. Europe is soon to open for it and it has 75 other trials it is starting for that brand alone. Hugin said this may make a huge difference in many cancer indications. Celgene also has six other drug discovery programs ongoing now, including stem cells. Cramer said betting against this is going to make the short sellers wrong. If you have been watching this show long enough or just reading our take on this, then you'll know he has been very positive on CELG many times. That's why this one was not even up 1% after Cramer interviewed its COO. CELG also has a $19 billion market cap now and you'll have to determine if you think the multiples are astronomical even for a high-growth biotech on your own.

Jon Ogg is a partner in 24/7 Wall St., LLC; he does not own securities in the companies he covers.